Eurobact 2: A worldwide cohort study on the Epidemiology and determinants of outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care.

The Eurobact 2 study will provide new insights on the management of critically ill patients with severe infections and difficult to treat pathogens. Eight years after the first Eurobact study the epidemiology of antibiotic resistance has changed. Meanwhile there have been advances in the management of patients with sepsis and microbiology laboratory techniques. Recently new antibiotic combinations have been made available for difficult to treat pathogens and an update on the management of patients with severe infections acquired in the hospital is required.

Each ICU will include 10 consecutive patients with HA-BSI or for 3 months maximum.

This is an observational study. No interventions or supplementary tests are required, everything should be anonymously collected from the patient's chart.

With support from around the globe, National coordinators in 16 different countries and counting, endorsement by the by the Infection section of the ESICM and the ESCMID Study Group for Infections in Critically Ill Patients (ESGCIP) we will provide with a well required update on Hospital Acquired Blood Stream Infections (HA-BSI) in the Intensive Care.

National coordinators and participating ICUs are currently being recruited. The study is expected to recruit patients from March 2019.

If you want to obtain more information or register your interest, please email us at eurobact@gmail.com

The Eurobact 1 study included 1156 patients from 162 ICUs in 24 countries. Click here to see the results and publications from the Eurobact 1 study.

Our committee

Primary investigators, organization, data management and statistical support

Alexis Tabah, MD – Brisbane, Australia.
Jean-François Timsit , MD, PhD – Paris, France.
Stephane Ruckly